Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Pralsetinib

These are related to the Pralsetinib news, in which you can learn about the updated information in Pralsetinib, to help you better understand and expand Pralsetinib market. Because the market for Pralsetinib is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 01 2025

    Drug Patent & Exclusivity Expiration Report - Week of Sep 01 2025

    2025-09-01

    This week, there are 10 drugs in the patent and exclusivity list. They are: - SUCAMPO PHARMA AMERICAS LLC's AMITIZA, containing active ingredient LUBIPROSTONE - GENENTECH INC's ERIVEDGE, containing active ingredient VISMODEGIB - GE HEALTHCARE's VIZAMYL, containing active ingredient FLUTEMETAMOL F-18 - AVERITAS PHARMA INC's QUTENZA, containing active ingredient CAPSAICIN - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's PRADAXA, containing active ingredient DABIGATRAN ETEXILATE MESYLATE - BAYER HEALTHCARE PHARMACEUTICALS INC's KERENDIA, containing active ingredient FINERENONE - VERTEX PHARMACEUTICALS INC's ORKAMBI, containing active ingredient IVACAFTOR; LUMACAFTOR - CURIUM US LLC's DETECTNET, containing active ingredient COPPER CU-64 DOTATATE - RIGEL PHARMACEUTICALS INC's GAVRETO, containing active ingredient PRALSETINIB - ASTELLAS PHARMA US INC's CRESEMBA, containing active ingredient ISAVUCONAZONIUM SULFATE Read More
  • Pralsetinib and NSCLC

    Pralsetinib and NSCLC

    2023-09-14

    Compounds with CAS RN 2097133-17-8, CAS RN 2778223-52-0 and CAS RN 35277-02-2 can be used to synthesize Read More
  • Advancements in Pralsetinib Production: The New Intermediates on The Block

    Advancements in Pralsetinib Production: The New Intermediates on The Block

    2023-09-04

    IntroductionPralsetinib, an innovative cancer-fighting drug, has been making significant strides in targeted oncology therapy—specifically against non-small cell lung cancer (NSCLC) with RET gene alterations. Pralsetinib's remarkable efficacy and ability to provide targeted treatment for cancer make Read More